SOUTH SAN FRANCISCO, CA – Sutro Biopharma , Inc. (NASDAQ:STRO), a company specializing in biological products with a market capitalization of $50.43 million, disclosed today the upcoming departure of ...

The Marlette Flume was hardly Nevada’s only 19th-century engineering wonder: the Silver State’s rise was built on ambitious ...

Sutro Biopharma, Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was ...

For several years past Adolph Sutro has been quietly buying up rare books and manuscripts at public and private sales through his agents and personally. The purchases, of course, are made in Europe.

Ra Capital's Peter Kolchinsky Opens New Position in Sutro Biopharma Peter Kolchinsky of Ra Capital Management added Sutro Biopharma (NASDAQ:STRO) to the hedge fund's £5.86 billion ($7.51 billion ...

Adolph S. Ochs, publisher of the New York Times and one of the most famous figures in the newspaper business of the past three decades, died here today at the age of 77.

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Sutro Biopharma, Inc. before investing. In this article, we go over a few key ...

With that in mind, let’s turn the clock back to UK’s first NCAA championship in 1948 with Adolph Rupp. A crowd of 15,000 fans greeted the University of Kentucky’s 1948 NCAA national ...

Most recently, he was principal of Sutro Elementary School in the Lyon County School District.In addition to his work in schools, Walker has been active in public service. He is a past president of ...

Sutro Biopharma had a negative net margin of 77.01% and a negative return on equity of 101.89%. The company had revenue of $14.00 million for the quarter, compared to analysts’ expectations of ...

The development of antibody-drug conjugates (ADCs) remains a central theme in ongoing research within the realm of ovarian cancer, and work examining different targets and sequencing considerations ...